Pneumology Department, Hospital Arnau de Vilanova, Valencia, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Spain.
Respiratory Department, Hospital de Alta Resolución de Loja, Loja (Granada), Spain.
Chest. 2020 May;157(5):1138-1146. doi: 10.1016/j.chest.2019.11.004. Epub 2019 Nov 22.
Control has been proposed as a dynamic tool that can capture changes in the clinical status of patients with COPD.
This prospective, multicenter, observational study aimed to compare changes in control over a 3-month period with changes in risk level, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage, and clinical phenotype (nonexacerbator, asthma-COPD overlap, or exacerbator with emphysema or with chronic bronchitis). Control was defined as the presence of low clinical impact, assessed according to the degree of dyspnea, use of rescue medication, physical activity and sputum color, and clinical stability assessed by clinical changes and exacerbations in the last 3 months. Impact and stability were alternatively assessed with COPD Assessment Test (CAT) scores.
We included 354 patients, with a mean FEV of 49.8% ± 16.9%. At 3 months, the proportion of controlled patients was 50.3% according to clinical evaluation and 47.8% according to CAT score. Eighty-seven patients (29.2%) changed their control status as assessed by clinical variables, and 85 patients (28.5%) changed their status according to CAT score. In contrast, the risk level only changed in 26 patients (8.7%) (P < .001), 27 patients (9.1%) experienced changes in their clinical phenotype (P < .001), and 59 patients (19.8%) experienced changes in their GOLD stage (P = .008). Patients who showed an improvement in control status had better CAT scores at the end of follow-up (P < .001).
In only 3 months, almost one-third of patients experienced changes in their control status. Changes in control status were significantly more frequent than changes in phenotype, risk level, and GOLD stage, and resulted in significant changes in health status.
控制被认为是一种动态工具,可以捕捉 COPD 患者临床状况的变化。
这是一项前瞻性、多中心、观察性研究,旨在比较 3 个月期间控制情况的变化与风险水平、全球慢性阻塞性肺疾病倡议(GOLD)分期和临床表型(非加重者、哮喘-COPD 重叠或伴有肺气肿或慢性支气管炎的加重者)的变化。控制是指根据呼吸困难程度、急救药物使用、体力活动和痰色评估的低临床影响,以及过去 3 个月内的临床变化和加重评估的临床稳定性来定义的。影响和稳定性也可以用 COPD 评估测试(CAT)评分来评估。
我们纳入了 354 名患者,平均 FEV 为 49.8%±16.9%。在 3 个月时,根据临床评估,控制患者的比例为 50.3%,根据 CAT 评分,控制患者的比例为 47.8%。87 名患者(29.2%)根据临床变量评估改变了他们的控制状态,85 名患者(28.5%)根据 CAT 评分改变了他们的状态。相比之下,风险水平仅在 26 名患者(8.7%)中发生变化(P<.001),27 名患者(9.1%)在临床表型上发生变化(P<.001),59 名患者(19.8%)在 GOLD 分期上发生变化(P=.008)。控制状态改善的患者在随访结束时 CAT 评分更好(P<.001)。
在仅 3 个月的时间内,近三分之一的患者控制状况发生变化。控制状态的变化明显比表型、风险水平和 GOLD 分期的变化更频繁,导致健康状况发生显著变化。